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Fungal pacemaker lead endocarditis is a fatal disease. Here we
present a case where an early diagnosis by blood culture and
transesophageal echocardiography resulted in a successful
outcome with antifungal therapy, without surgical explantation.
2. Case report
An eighty-six-year old immunocompetent diabetic male with
permanent pacing for 3 years was admitted with generalized
weakness and fever for one week. Baseline investigations
revealed total leukocyte count of 10,000 (70% neutrophils) and
raised CRP. Blood culture grew Candida tropicalis sensitive to* Corresponding author.
E-mail address: shilpaputhran41@gmail.com (S. Puthran).
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0019-4832/# 2015 Cardiological Society of India. Published by Elsevieﬂucytosine, amphotericin B, ﬂuconazole, voriconazole, and
caspofungin. Transthoracic echocardiography showed multi-
ple large masses on the pacemaker electrode in the right
atrium and ventricle, which were highly suggestive of
vegetation. A subsequent transesophageal echocardiography
conﬁrmed these ﬁndings (Fig. 1). In view of advanced age and
high risk of surgical mortality associated with explantation of
pacemaker lead, both the patient and his family refused
surgery and opted for aggressive antifungal therapy instead.
The patient was treated with intravenous caspofungin 70 mg
on Day 1 and 50 mg daily for 10 days followed by intravenous
ﬂuconazole for 15 days. He was subsequently put on oral
ﬂuconazole (200 mg b.i.d) for two months. A repeat transeso-
phageal echocardiography during a follow-up visit, two
months post-discharge, showed no intracardiac mass (Fig. 2)
and the patient remained asymptomatic.r B.V. All rights reserved.
Fig. 1 – Echocardiography showing multiple mass around
pacemaker lead.
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The overall incidence of associated infections post pacemaker
surgeries has been quoted as 0–12.6%,1,2 with rates ranging
from 0.13% to 19.9% for permanent pacemakers (PPMs) and
0.2% to 7.2% for implantable cardioverter-deﬁbrillators (ICDs).3
Cardiac rhythm management device (CRMD) related endocar-
ditis accounted for 10% of such infections.2,3 Fungal infections,
though rare, are found documented in random case reports
and Candida species were found to be the major pathogens in
such cases.3
Excluding our current case, a literature search in the
PubMed database elicited eighteen published cases of Candida
endocarditis with indwelling PPMs and ICDs. Fifteen of these
cases were summarized in a review by Ahmad Halawa et al.,3
covering publications from 1969 to 2009. The sixteenth case
was published in 2013 by Tascini et al.,2 and Rivera et al.
reported the eighteenth case in 2014.14 Our review did not
include cases of prosthetic valve fungal endocarditis without
CRMDs.
An overview of the sixteen cases has been summarized in
this report mainly from the ﬁndings of Halawa et al.3 and Tascini
et al.2 There were ﬁfteen males between 38 and 87 years and oneFig. 2 – Echocardiography showing complete resolution of
mass around pacemaker lead.female aged 75 years. Lead vegetations were detected by
echocardiography in ﬁfteen patients and during autopsy in
one. There was equal prevalence of Candida albican and non-
albican pathogens (8 patients each). Amongst the non-albicans,
C. parapsilosis was isolated in four cases (25%), C. tropicalis in two
cases (12.5%), and C. glabrata in two cases (12.5%). Mixed
infections were present in two patients (12.5%), one with C.
albicans and C. glabrata and the other with C. albicans and
S. epidermidis. Thirteen of the sixteen cases received speciﬁc
antifungal treatment with amphotericin B, ﬂuconazole, 5-
ﬂucytosine, and echinocandins either alone or in combinations.
Four patients were treated with only amphotericin B. Three
patients were treated with only ﬂuconazole. Two patients
received a combination of amphotericin B with ﬂuconazole and
two others a combination of amphotericin B, 5-ﬂucytosine and
ﬂuconazole. In the two patients treated with echinocandins,
one received caspofungin followed by ﬂuconazole and posaco-
nazole, whereas the other was initially treated with ﬂuconazole
followed by micafungin. Three of the sixteen patients had no
documentation of being treated with antifungals, as therapy
was undeﬁned for two patients and one received only
antibiotics. Survival rate in these sixteen cases was 50% with
eight patients surviving. However, it should be noted that the
cause of death in two cases was postsurgical complications and
bacteremia and not primarily fungal endocarditis. In contrast to
our current case, it is interesting to note that none of the above
sixteen cases were treated solely by medical management for
Candida endocarditis. Surgical device explantation was per-
formed in thirteen cases; one patient refused surgery who later
died of multiorgan failure, one patient was considered
medically unﬁt for surgery who subsequently died of a fatal
stroke, and one died due to congestive heart failure prior to any
planned intervention.2,3
The more recent eighteenth published case in 2014 by
Rivera et al.14 was of a 60-yearold female with an ICD and a
blood culture positive for C. albicans. The patient underwent
device removal and was managed with micafungin for 2 weeks
followed by ﬂuconazole for 6 weeks.14
Our search also revealed ﬁve cases of noncandidial fungal
pacemaker endocarditis. Four were females between 30 and 80
years and one was a male aged 65 years. Four were cases of
Aspergillus infections and one was infected with Petriellidium
boydii. Amongst the Aspergillus infections, speciation was
documented in only two cases, one each with Aspergillus
fumigatus and Aspergillus ﬂavus, respectively. Other than the
lone case of A. fumigatus, which was treated with amphotericin
B, none of the other four patients received antifungals. Device
explantation was performed in two cases, one of which was
the case diagnosed with A. fumigatus infection. Death occurred
in all cases except the lone case of A. fumigatus, which was
treated with amphotericin B.4–8
Additionally, we also found another case reported in 1977 of
a 70-year old female with pacemaker who underwent device
explantation for infection and subsequently expired due to
pulmonary embolism. The patient was neither diagnosed nor
treated for fungal infections. Postmortem analysis of the
pacemaker thrombus revealed fungi. However, there was no
documentation of either the genus or species of fungus.6,9
Diagnosis of fungal endocarditis is difﬁcult due to low
positivity rates of blood cultures.4,10 Speciation should be
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prevalence of non-albicans. Decisions to investigate further and
treat should be based on a high index of suspicion in the
presence of indwelling cardiac devices, unexplained fever,
increasing age, and associated clinical risk factors even in
culture negative cases. Some of the risk factors often cited are
immunosuppression, diabetes mellitus, use of oral anticoagu-
lants, indwelling cardiac device manipulation, lack of perioper-
ative antimicrobial prophylaxis, and Staphylococcus aureus
bacteremia.2,4,6,10,11 Transthoracic and transesophageal echo-
cardiography are also important diagnostic tools, which should
be used more effectively in routine clinical settings for picking
up presence of suspect vegetations on implanted devices.
The IDSA 2009 guidelines for management of Candida
endocarditis recommend LFAmB 3–5 mg/kg, with or without 5-
FC 25 mg/kg qid, or AmB-d 0.6–1 mg/kg daily, with or without
5-FC 25 mg/kg qid, or an echinocandin followed by a step-
down therapy to ﬂuconazole 400–800 mg daily in stable
patients with negative blood culture. However, the guidelines
strongly recommend surgical removal of the infected device
along with a daily dose of ﬂuconazole 400–800 mg for long-
term suppression.12
The ESCMID 2012 guidelines also recommend surgical
explantation of infected devices along with liposomal ampho-
tericin B or caspofungin, either singly or in combination with
ﬂucytosine followed by a suppression therapy with ﬂucona-
zole. In cases where surgery was contraindicated due to
presence of comorbidities, caspofungin and liposomal am-
photericin B were used successfully with or without subse-
quent life-long suppressive therapy with ﬂuconazole.13
A recent scientiﬁc statement by the American Heart
Association (AHA) published in 2015 recommends complete
device and lead removal for all patients with cardiovascular
implantable electronic device (CIED) infection followed by at
least 14 days of appropriate antimicrobial therapy after CIED
removal for bloodstream infection. It also advocates considering
long-term suppressive therapy for patients who have CIED
infection and are not candidates for complete device removal.
This is in reference to those who have a limited life expectancy or
have refused device removal, as was the case with our patient.15
A limitation of this case report is that the patient was lost to
follow-up 3 months post-discharge due to which long-term
implications on leaving the device in situ cannot be com-
mented upon. However, the last echocardiogram and routine
laboratory investigations did not depict presence of any
obvious infection during the follow-up period.
4. Conclusion
Cases of fungal pacemaker endocarditis are on the rise due to
increasing usage of in vivo cardiac devices and can no longer
be considered a rare occurrence. Though surgical removal of
the infected device combined with medical management still
remains the mainstay of treatment, a high index of clinical
suspicion based on presence of risk factors, prompt diagnosis by
microscopy, and echocardiography along with early initiation of
antifungal agents can result in complete resolution anddecreased mortality by medical management alone, especially
in those patients who have a limited life expectancy or have
refused device removal. However, periodic long-term follow-up
of such patients for evaluation of CIED infections becomes
imperative.
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